Dr. Lal PathLabs Limited (LALPATHLAB) Fair Value & Analysis
Healthcare · IN · Market cap ₹276B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price +5.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹1,308 – ₹995,642 · fair‑value band ₹498.82 – ₹831.37 · the ₹1,650 price screens above the ₹665.09 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Dr. Lal PathLabs Limited (LALPATHLAB) currently trades at ₹1,650, while our model-based Fair Value estimate is ₹665.09 — implying the stock looks roughly 59.7% overvalued today. We read business quality at 58/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Dr. Lal PathLabs Limited generated revenue of ₹27.6B at a net margin of 18.3%. Revenue grew 16.6% year over year. It earns a return on equity of 21.5%. The balance sheet holds a net cash position of ₹7.1B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Dr. Lal PathLabs Limited reported revenue of ₹27.6B in FY2026 versus ₹20.9B in FY2022, a compound +7.3%/yr. Reported net income was ₹5.0B in FY2026, compounding +10.0%/yr from FY2022.
Is LALPATHLAB fairly valued? → Check now
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $464.01 | $326.81 | -30% |
| Danaher Corporation DHR | $178.19 | $112.34 | -37% |
| WuXi AppTec Co 2359 | HK$152.80 | HK$120.99 | -21% |
| IDEXX Laboratories, Inc IDXX | $562.16 | $190.95 | -66% |
| Lonza Group LZAGY | $61.97 | $14.23 | -77% |
| Agilent Technologies, Inc A | $131.62 | $60.93 | -54% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Dr. Lal PathLabs Limited (LALPATHLAB) undervalued?
What is the fair value of LALPATHLAB?
What is the quality score of LALPATHLAB?
What is the revenue of Dr. Lal PathLabs Limited (LALPATHLAB)?
What is the net profit margin of LALPATHLAB?
Does Dr. Lal PathLabs Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.